Pfizer Ventures and Chiesi Ventures-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.
US-based gene therapy developer 4D Molecular Therapeutics (4DMT) refiled for an initial public offering on Tuesday, giving pharmaceutical firms Pfizer and Chiesi Group the chance to exit. The company has filed to raise up to $75m in an offering on the Nasdaq Global Market, the same market where it originally filed for a $100m IPO…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.